加齢黄斑変性症（AMD）治療薬の世界市場：シェア、規模、動向、産業分析レポート、医薬品別（Lucentis、Eylea、Avastin、その他）、製品別、投与経路別、流通チャネル別、地域別、セグメント予測（2022年～2030年）

世界の加齢黄斑変性症（AMD）治療薬の市場規模は、2030年までに144億3,000万米ドルに達すると予想されています。

当レポートでは、世界の加齢黄斑変性症（AMD）治療薬市場を調査しており、市場の概要、市場規模や予測、動向、成長要因および抑制要因、医薬品・製品・投与経路・流通チャネル・地域別などの分析、さらに企業プロファイルなどを提供しています。

目次

第1章 イントロダクション

• レポートの説明
  • 調査の目的
  • 市場範囲
  • 前提条件
• ステークホルダー

第2章 エグゼクティブサマリー

• 市場のハイライト

第3章 調査手法

• 概要
  • データマイニング
• 情報源
  • 一次情報源
  • 二次情報源

第4章 世界の加齢黄斑変性症（AMD）治療薬市場の洞察

• 加齢黄斑変性症（AMD）治療薬-業界のスナップショット
• 加齢黄斑変性症（AMD）治療薬市場力学
  • 推進要因と機会
  • 抑制要因と課題
• ポーターのファイブフォース分析
  • 供給企業の交渉力
  • 新規参入者の脅威
  • 買い手の交渉力
  • 代替の脅威
  • 既存企業間の競争
• PESTLE分析
• 加齢黄斑変性症（AMD）治療薬業界の動向
• バリューチェーン分析
• COVID-19影響分析

第5章 世界の加齢黄斑変性症（AMD）治療薬市場：製品別

• 主な調査結果
• イントロダクション
  • 世界の加齢黄斑変性症（AMD）治療薬市場、製品別（2018年～2030年）
• ウェット型AMD
  • 世界の加齢黄斑変性症（AMD）治療薬市場、ウェット型AMD別、地域別（2018年～2030年）
• ドライ型AMD
  • 世界の加齢黄斑変性症（AMD）治療薬市場、ドライ型AMD別、地域別（2018年～2030年）

第6章 世界の加齢黄斑変性症（AMD）治療薬市場：医薬品別

• 主な調査結果
• イントロダクション
  • 世界の加齢黄斑変性症（AMD）治療薬市場、医薬品別（2018年～2030年）
• Lucentis
  • 世界の加齢黄斑変性症（AMD）治療薬市場、Lucentis別、地域別（2018年～2030年）
• Eylea
  • 世界の加齢黄斑変性症（AMD）治療薬市場、Eylea別、地域別（2018年～2030年）
• Avastin
  • 世界の加齢黄斑変性症（AMD）治療薬市場、Avastin別、地域別（2018年～2030年）
• その他
  • 世界の加齢黄斑変性症（AMD）治療薬市場、その他、地域別（2018年～2030年）

第7章 世界の加齢黄斑変性症（AMD）治療薬市場：投与経路別

• 主な調査結果
• イントロダクション
  • 世界の加齢黄斑変性症（AMD）治療薬市場、投与経路別（2018年～2030年）
• 静脈内注射
  • 世界の加齢黄斑変性症（AMD）治療薬市場、静脈内注射別、地域別（2018年～2030年）
• 硝子体内注射
  • 世界の加齢黄斑変性症（AMD）治療薬市場、硝子体内注射別、地域別（2018年～2030年）

第8章 世界の加齢黄斑変性症（AMD）治療薬市場：流通チャネル別

• 主な調査結果
• イントロダクション
  • 世界の加齢黄斑変性症（AMD）治療薬市場、流通チャネル別（2018年～2030年）
• 病院薬局
  • 世界の加齢黄斑変性症（AMD）治療薬市場、病院薬局別、地域別（2018年～2030年）
• 小売薬局
  • 世界の加齢黄斑変性症（AMD）治療薬市場、小売薬局別、地域別（2018年～2030年）
• オンライン薬局
  • 世界の加齢黄斑変性症（AMD）治療薬市場、オンライン薬局別、地域別（2018年～2030年）

第9章 世界の加齢黄斑変性症（AMD）治療薬市場：地域別

• 主な調査結果
• イントロダクション
  • 加齢黄斑変性症（AMD）治療薬市場評価、地域別（2018年～2030年）
• 加齢黄斑変性症（AMD）治療薬市場-北米
  • 北米：加齢黄斑変性症（AMD）治療薬市場、製品別（2018年～2030年）
  • 北米：加齢黄斑変性症（AMD）治療薬市場、流通チャネル別（2018年～2030年）
  • 北米：加齢黄斑変性症（AMD）治療薬市場、医薬品別（2018年～2030年）
  • 北米：加齢黄斑変性症（AMD）治療薬市場、投与経路別（2018年～2030年）
  • 加齢黄斑変性症（AMD）治療薬市場-米国
  • 加齢黄斑変性症（AMD）治療薬市場-カナダ
• 加齢黄斑変性症（AMD）治療薬市場-欧州
  • 欧州：加齢黄斑変性症（AMD）治療薬市場、製品別（2018年～2030年）
  • 欧州：加齢黄斑変性症（AMD）治療薬市場、流通チャネル別（2018年～2030年）
  • 欧州：加齢黄斑変性症（AMD）治療薬市場、医薬品別（2018年～2030年）
  • 欧州：加齢黄斑変性症（AMD）治療薬市場、投与経路別（2018年～2030年）
  • 加齢黄斑変性症（AMD）治療薬市場-英国
  • 加齢黄斑変性症（AMD）治療薬市場-フランス
  • 加齢黄斑変性症（AMD）治療薬市場-ドイツ
  • 加齢黄斑変性症（AMD）治療薬市場-イタリア
  • 加齢黄斑変性症（AMD）治療薬市場-スペイン
  • 加齢黄斑変性症（AMD）治療薬市場-オランダ
  • 加齢黄斑変性症（AMD）治療薬市場-ロシア
• 加齢黄斑変性症（AMD）治療薬市場-アジア太平洋
  • アジア太平洋：加齢黄斑変性症（AMD）治療薬市場、製品別（2018年～2030年）
  • アジア太平洋：加齢黄斑変性症（AMD）治療薬市場、流通チャネル別（2018年～2030年）
  • アジア太平洋：加齢黄斑変性症（AMD）治療薬市場、医薬品別（2018年～2030年）
  • アジア太平洋：加齢黄斑変性症（AMD）治療薬市場、投与経路別（2018年～2030年）
  • 加齢黄斑変性症（AMD）治療薬市場-中国
  • 加齢黄斑変性症（AMD）治療薬市場-インド
  • 加齢黄斑変性症（AMD）治療薬市場-日本
  • 加齢黄斑変性症（AMD）治療薬市場-マレーシア
  • 加齢黄斑変性症（AMD）治療薬市場-インドネシア
  • 加齢黄斑変性症（AMD）治療薬市場-韓国
• 加齢黄斑変性症（AMD）治療薬市場-中東およびアフリカ
  • 中東・アフリカ：加齢黄斑変性症（AMD）治療薬市場、製品別（2018年～2030年）
  • 中東・アフリカ：加齢黄斑変性症（AMD）治療薬市場、流通チャネル別（2018年～2030年）
  • 中東・アフリカ：加齢黄斑変性症（AMD）治療薬市場、医薬品別（2018年～2030年）
  • 中東・アフリカ：加齢黄斑変性症（AMD）治療薬市場、投与経路別（2018年～2030年）
  • 加齢黄斑変性症（AMD）治療薬市場-サウジアラビア
  • 加齢黄斑変性症（AMD）治療薬市場-南アフリカ
  • 加齢黄斑変性症（AMD）治療薬市場-イスラエル
  • 加齢黄斑変性症（AMD）治療薬市場-アラブ首長国連邦
• 加齢黄斑変性症（AMD）治療薬市場-ラテンアメリカ
  • ラテンアメリカ：加齢黄斑変性症（AMD）治療薬市場、製品別（2018年～2030年）
  • ラテンアメリカ：加齢黄斑変性症（AMD）治療薬市場、流通チャネル別（2018年～2030年）
  • ラテンアメリカ：加齢黄斑変性症（AMD）治療薬市場、医薬品別（2018年～2030年）
  • ラテンアメリカ：加齢黄斑変性症（AMD）治療薬市場、投与経路別（2018年～2030年）
  • 加齢黄斑変性症（AMD）治療薬市場-メキシコ
  • 加齢黄斑変性症（AMD）治療薬市場-ブラジル
  • 加齢黄斑変性症（AMD）治療薬市場-アルゼンチン

第10章 競合情勢

• 拡大・買収分析
  • 拡大
  • 買収
• パートナーシップ/コラボレーション/契約/展示会

第11章 企業プロファイル

• Acucela Inc.
• Alimera Sciences Inc.
• ALLERGAN
• Bausch & Lomb Incorporated
• Bayer AG
• F. Hoffmann La Roche
• GlaxoSmithKline PLC
• Novartis AG
• Ophthotech Corporation
• Pfizer Inc
• Regeneron Pharmaceuticals
• Rxi Pharmaceuticals Inc.
• Santen Pharmaceuticals Co.
• Valeant Pharmaceuticals International, Inc.

List of Tables

• Table 1 Global Age-related Macular Degeneration (AMD) Market, by Product, by Region, 2018 - 2030 (USD Billion)
• Table 2 Global Age-related Macular Degeneration (AMD) Market, by Drugs, by Region, 2018 - 2030 (USD Billion)
• Table 3 Global Age-related Macular Degeneration (AMD) Market, by Route of Administration, by Region, 2018 - 2030 (USD Billion)
• Table 4 Global Age-related Macular Degeneration (AMD) Market, by Distribution Channel, by Region, 2018 - 2030 (USD Billion)
• Table 5 Age-related Macular Degeneration (AMD) Market Assessment, By Geography, 2018 - 2030 (USD Billion)
• Table 6 North America: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
• Table 7 North America: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
• Table 8 North America: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
• Table 9 North America: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
• Table 10 U.S.: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
• Table 11 U.S.: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
• Table 12 U.S.: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
• Table 13 U.S.: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
• Table 14 Canada: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
• Table 15 Canada: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
• Table 16 Canada: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
• Table 17 Canada: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
• Table 18 Europe: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
• Table 19 Europe: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
• Table 20 Europe: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
• Table 21 Europe: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
• Table 22 Germany: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
• Table 23 Germany: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
• Table 24 Germany: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
• Table 25 Germany: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
• Table 26 France: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
• Table 27 France: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
• Table 28 France: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
• Table 29 France: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
• Table 30 UK: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
• Table 31 UK: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
• Table 32 UK: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
• Table 33 UK: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
• Table 34 Italy: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
• Table 35 Italy: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
• Table 36 Italy: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
• Table 37 Italy: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
• Table 38 Netherlands: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
• Table 39 Netherlands: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
• Table 40 Netherlands: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
• Table 41 Netherlands: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
• Table 42 Spain: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
• Table 43 Spain: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
• Table 44 Spain: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
• Table 45 Spain: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
• Table 46 Russia: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
• Table 47 Russia: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
• Table 48 Russia: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
• Table 49 Russia: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
• Table 50 Asia Pacific: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
• Table 51 Asia Pacific: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
• Table 52 Asia Pacific: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
• Table 53 Asia Pacific: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
• Table 54 China: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
• Table 55 China: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
• Table 56 China: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
• Table 57 China: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
• Table 58 Japan: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
• Table 59 Japan: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
• Table 60 Japan: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
• Table 61 Japan: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
• Table 62 India: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
• Table 63 India: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
• Table 64 India: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
• Table 65 India: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
• Table 66 Indonesia: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
• Table 67 Indonesia: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
• Table 68 Indonesia: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
• Table 69 Indonesia: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
• Table 70 Malaysia: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
• Table 71 Malaysia: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
• Table 72 Malaysia: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
• Table 73 Malaysia: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
• Table 74 South Korea: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
• Table 75 South Korea: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
• Table 76 South Korea: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
• Table 77 South Korea: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
• Table 78 Latin America: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
• Table 79 Latin America: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
• Table 80 Latin America: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
• Table 81 Latin America: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
• Table 82 Brazil: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
• Table 83 Brazil: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
• Table 84 Brazil: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
• Table 85 Brazil: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
• Table 86 Mexico: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
• Table 87 Mexico: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
• Table 88 Mexico: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
• Table 89 Mexico: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
• Table 90 Argentina: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
• Table 91 Argentina: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
• Table 92 Argentina: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
• Table 93 Argentina: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
• Table 94 Middle East & Africa: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
• Table 95 Middle East & Africa: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
• Table 96 Middle East & Africa: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
• Table 97 Middle East & Africa: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
• Table 98 UAE: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
• Table 99 UAE: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
• Table 100 UAE: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
• Table 101 UAE: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
• Table 102 Saudi Arabia: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
• Table 103 Saudi Arabia: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
• Table 104 Saudi Arabia: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
• Table 105 Saudi Arabia: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
• Table 106 South Africa: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
• Table 107 South Africa: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
• Table 108 South Africa: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
• Table 109 South Africa: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
• Table 110 Israel: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
• Table 111 Israel: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
• Table 112 Israel: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
• Table 113 Israel: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)

List of Figures

Figure 1. Global Age-related Macular Degeneration (AMD) Market, 2018 - 2030 (USD Billion)

Figure 2. Integrated Ecosystem

Figure 3. Research Methodology: Top-Down & Bottom-Up Distribution Channel

Figure 4. Market by Geography

Figure 5. Porter's Five Forces

Figure 6. Market by Product

Figure 7. Global Age-related Macular Degeneration (AMD) Market, by Product, 2021 & 2030 (USD Billion)

Figure 8. Market by Distribution Channel

Figure 9. Global Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2021 & 2030 (USD Billion)

Figure 10. Market by Drugs

Figure 11. Global Age-related Macular Degeneration (AMD) Market, by Drugs, 2021 & 2030 (USD Billion)

Figure 12. Market by Route of Administration

Figure 13. Global Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2021 & 2030 (USD Billion)

Figure 14. Age-related Macular Degeneration (AMD) Market Assessment, By Geography, 2018 - 2030 (USD Billion)

Figure 15. Strategic Analysis - Age-related Macular Degeneration (AMD) Market

The global Age-related Macular Degeneration (AMD) market size is expected to reach USD 14.43 billion by 2030 according to a new study by Polaris Market Research. The report "Age-related Macular Degeneration (AMD) Market Share, Size, Trends, Industry Analysis Report, By Drugs (Lucentis, Eylea, Avastin, Others); By Product; By Route of Administration; By Distribution Channel; By Region; Segment Forecast, 2022 - 2030" gives a detailed insight into current market dynamics and provides analysis on future market growth.

The AMD industry is boosted by an increase in the frequency of eye-related diseases and an increase in the number of refractive eye surgeries for eye disorders. As per the WHO, in 2019, around 2.2 billion people from across the globe have been suffering from one or the other kind of visual impairment, and out of this, 123.7 million people have uncorrected refractive errors.

The different type of refractive errors includes nearsightedness (myopia), farsightedness (hyperopia), astigmatism, and presbyopia. Glasses, contact lenses, and laser eye surgery are the commonly available treatment for the correction of refractive errors. Due to the discomfort offered by wearing glasses and contact lenses, more and more people are inclined towards the adoption of refractive eye surgery to correct their refractive errors.

Furthermore, as per the American Refractive Surgery Council, in 2017, more than 29 million LASIK procedures were performed in the US. As per the American Association of Ophthalmology, in the US, 70% to 80% of people with refractive error opt for LASIK eye surgery, and 20% to 30% opt for PRK surgery. Intravitreal wearables segment accounted for the leading share in the market. The intravitreal segment is growing in popularity because tailored drug administration makes it more effective. In addition, the various anti-VEGF injections are given intravitreal or intraocularly. Anti-Vascular Endothelial Growth Factor medications are used to treat wet AMD (anti-VEGF).

Lucentis (ranibizumab) and Eylea (aflibercept) are two FDA-approved medications that are commonly prescribed for AMD. Avastin (bevacizumab), an off-label medication, is also widely utilized. Wet AMD is also treated with photodynamic therapy (PDT), which reduces the progression of vision impairment.

Industry players such as F. Hoffmann La Roche, Alimera Sciences Inc., ALLERGAN, Regeneron Pharmaceuticals, Bausch & Lomb Incorporated, Bayer AG, GlaxoSmithKline PLC, Novartis AG, Acucela Inc., Ophthotech Corporation, Pfizer Inc, Rxi Pharmaceuticals Inc., Santen Pharmaceuticals Co., and Valeant Pharmaceuticals International, Inc. are some key players operating in the industry. In January 2021, Novartis started phase III trials of its candidate "brolucizumab" for the cure of AMD to assess its tolerability and effectiveness.

Polaris Market Research has segmented the Age-related Macular Degeneration (AMD) Market report based on product, drugs, route of administration, distribution channel, and region:

Age-related Macular Degeneration (AMD), Product Outlook (Revenue - USD Billion, 2018 - 2030)

Wet AMD

Dry AMD

Age-related Macular Degeneration (AMD), Drugs Outlook (Revenue - USD Billion, 2018 - 2030)

Lucentis

Eylea

Avastin

Others

Age-related Macular Degeneration (AMD), Route of Administration Outlook (Revenue - USD Billion, 2018 - 2030)

Intravenous

Intravitreal

Age-related Macular Degeneration (AMD), Distribution Channel Outlook (Revenue - USD Billion, 2018 - 2030)

Hospital Pharmacies

Retail Pharmacies

Online Pharmacies

Age-related Macular Degeneration (AMD), Regional Outlook (Revenue - USD Billion, 2018 - 2030)

North America

U.S.

Canada

Europe

France

Germany

UK

Italy

Spain

Netherlands

Russia

Asia Pacific

China

India

Japan

Malaysia

South Korea

Indonesia

Latin America

Mexico

Brazil

Argentina

Middle East & Africa

UAE

Saudi Arabia

Israel

South Africa

Table of Contents

1. Introduction

• 1.1. Report Description
  • 1.1.1. Objectives of the Study
  • 1.1.2. Market Scope
  • 1.1.3. Assumptions
• 1.2. Stakeholders

2. Executive Summary

• 2.1. Market Highlights

3. Research Methodology

• 3.1. Overview
  • 3.1.1. Data Mining
• 3.2. Data Sources
  • 3.2.1. Primary Sources
  • 3.2.2. Secondary Sources

4. Global Age-related Macular Degeneration (AMD) Market Insights

• 4.1. Age-related Macular Degeneration (AMD) - Industry Snapshot
• 4.2. Age-related Macular Degeneration (AMD) Market Dynamics
  • 4.2.1. Drivers and Opportunities
    • 4.2.1.1. Increasing geriatric population
    • 4.2.1.2. Rising demand from the US, European and Asian population
  • 4.2.2. Restraints and Challenges
    • 4.2.2.1. High price for the medicines for AMD
• 4.3. Porter's Five Forces Analysis
  • 4.3.1. Bargaining Power of Suppliers (Moderate)
  • 4.3.2. Threats of New Entrants: (Low)
  • 4.3.3. Bargaining Power of Buyers (Moderate)
  • 4.3.4. Threat of Substitute (Moderate)
  • 4.3.5. Rivalry among existing firms (High)
• 4.4. PESTLE Analysis
• 4.5. Age-related Macular Degeneration (AMD) Industry Trends
• 4.6. Value Chain Analysis
• 4.7. COVID-19 Impact Analysis

5. Global Age-related Macular Degeneration (AMD) Market, by Product

• 5.1. Key Findings
• 5.2. Introduction
  • 5.2.1. Global Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
• 5.3. Wet AMD
  • 5.3.1. Global Age-related Macular Degeneration (AMD) Market, by Wet AMD, by Region, 2018 - 2030 (USD Billion)
• 5.4. Dry AMD
  • 5.4.1. Global Age-related Macular Degeneration (AMD) Market, by Dry AMD, by Region, 2018 - 2030 (USD Billion)

6. Global Age-related Macular Degeneration (AMD) Market, by Drugs

• 6.1. Key Findings
• 6.2. Introduction
  • 6.2.1. Global Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
• 6.3. Lucentis
  • 6.3.1. Global Age-related Macular Degeneration (AMD) Market, by Lucentis, by Region, 2018 - 2030 (USD Billion)
• 6.4. Eylea
  • 6.4.1. Global Age-related Macular Degeneration (AMD) Market, by Eylea, by Region, 2018 - 2030 (USD Billion)
• 6.5. Avastin
  • 6.5.1. Global Age-related Macular Degeneration (AMD) Market, by Avastin, by Region, 2018 - 2030 (USD Billion)
• 6.6. Others
  • 6.6.1. Global Age-related Macular Degeneration (AMD) Market, by Others, by Region, 2018 - 2030 (USD Billion)

7. Global Age-related Macular Degeneration (AMD) Market, by Route of Administration

• 7.1. Key Findings
• 7.2. Introduction
  • 7.2.1. Global Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
• 7.3. Intravenous
  • 7.3.1. Global Age-related Macular Degeneration (AMD) Market, by Intravenous, by Region, 2018 - 2030 (USD Billion)
• 7.4. Intravitreal
  • 7.4.1. Global Age-related Macular Degeneration (AMD) Market, by Intravitreal, by Region, 2018 - 2030 (USD Billion)

8. Global Age-related Macular Degeneration (AMD) Market, by Distribution Channel

• 8.1. Key Findings
• 8.2. Introduction
  • 8.2.1. Global Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
• 8.3. Hospital Pharmacies
  • 8.3.1. Global Age-related Macular Degeneration (AMD) Market, by Hospital Pharmacies, by Region, 2018 - 2030 (USD Billion)
• 8.4. Retail Pharmacies
  • 8.4.1. Global Age-related Macular Degeneration (AMD) Market, by Retail Pharmacies, by Region, 2018 - 2030 (USD Billion)
• 8.5. Online Pharmacies
  • 8.5.1. Global Age-related Macular Degeneration (AMD) Market, by Online Pharmacies, by Region, 2018 - 2030 (USD Billion)

9. Global Age-related Macular Degeneration (AMD) Market, by Geography

• 9.1. Key findings
• 9.2. Introduction
  • 9.2.1. Age-related Macular Degeneration (AMD) Market Assessment, By Geography, 2018 - 2030 (USD Billion)
• 9.3. Age-related Macular Degeneration (AMD) Market - North America
  • 9.3.1. North America: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
  • 9.3.2. North America: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • 9.3.3. North America: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
  • 9.3.4. North America: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • 9.3.5. Age-related Macular Degeneration (AMD) Market - U.S.
    • 9.3.5.1. U.S.: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
    • 9.3.5.2. U.S.: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 9.3.5.3. U.S.: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
    • 9.3.5.4. U.S.: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • 9.3.6. Age-related Macular Degeneration (AMD) Market - Canada
    • 9.3.6.1. Canada: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
    • 9.3.6.2. Canada: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 9.3.6.3. Canada: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
    • 9.3.6.4. Canada: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
• 9.4. Age-related Macular Degeneration (AMD) Market - Europe
  • 9.4.1. Europe: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
  • 9.4.2. Europe: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • 9.4.3. Europe: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
  • 9.4.4. Europe: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • 9.4.5. Age-related Macular Degeneration (AMD) Market - UK
    • 9.4.5.1. UK: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
    • 9.4.5.2. UK: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 9.4.5.3. UK: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
    • 9.4.5.4. UK: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • 9.4.6. Age-related Macular Degeneration (AMD) Market - France
    • 9.4.6.1. France: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
    • 9.4.6.2. France: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 9.4.6.3. France: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
    • 9.4.6.4. France: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • 9.4.7. Age-related Macular Degeneration (AMD) Market - Germany
    • 9.4.7.1. Germany: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
    • 9.4.7.2. Germany: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 9.4.7.3. Germany: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
    • 9.4.7.4. Germany: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • 9.4.8. Age-related Macular Degeneration (AMD) Market - Italy
    • 9.4.8.1. Italy: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
    • 9.4.8.2. Italy: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 9.4.8.3. Italy: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
    • 9.4.8.4. Italy: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • 9.4.9. Age-related Macular Degeneration (AMD) Market - Spain
    • 9.4.9.1. Spain: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
    • 9.4.9.2. Spain: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 9.4.9.3. Spain: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
    • 9.4.9.4. Spain: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • 9.4.10. Age-related Macular Degeneration (AMD) Market - Netherlands
    • 9.4.10.1. Netherlands: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
    • 9.4.10.2. Netherlands: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 9.4.10.3. Netherlands: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
    • 9.4.10.4. Netherlands: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • 9.4.11. Age-related Macular Degeneration (AMD) Market - Russia
    • 9.4.11.1. Russia: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
    • 9.4.11.2. Russia.: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 9.4.11.3. Russia: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
    • 9.4.11.4. Russia: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
• 9.5. Age-related Macular Degeneration (AMD) Market - Asia Pacific
  • 9.5.1. Asia Pacific: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
  • 9.5.2. Asia Pacific: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • 9.5.3. Asia Pacific: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
  • 9.5.4. Asia Pacific: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • 9.5.5. Age-related Macular Degeneration (AMD) Market - China
    • 9.5.5.1. China: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
    • 9.5.5.2. China.: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 9.5.5.3. China: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
    • 9.5.5.4. China: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • 9.5.6. Age-related Macular Degeneration (AMD) Market - India
    • 9.5.6.1. India: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
    • 9.5.6.2. India.: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 9.5.6.3. India: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
    • 9.5.6.4. India: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • 9.5.7. Age-related Macular Degeneration (AMD) Market - Japan
    • 9.5.7.1. Japan: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
    • 9.5.7.2. Japan.: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 9.5.7.3. Japan: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
    • 9.5.7.4. Japan: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • 9.5.8. Age-related Macular Degeneration (AMD) Market - Malaysia
    • 9.5.8.1. Malaysia: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
    • 9.5.8.2. Malaysia.: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 9.5.8.3. Malaysia: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
    • 9.5.8.4. Malaysia: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • 9.5.9. Age-related Macular Degeneration (AMD) Market - Indonesia
    • 9.5.9.1. Indonesia: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
    • 9.5.9.2. Indonesia.: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 9.5.9.3. Indonesia: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
    • 9.5.9.4. Indonesia: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • 9.5.10. Age-related Macular Degeneration (AMD) Market - South Korea
    • 9.5.10.1. South Korea: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
    • 9.5.10.2. South Korea.: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 9.5.10.3. South Korea: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
    • 9.5.10.4. South Korea: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
• 9.6. Age-related Macular Degeneration (AMD) Market - Middle East & Africa
  • 9.6.1. Middle East & Africa: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
  • 9.6.2. Middle East & Africa: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • 9.6.3. Middle East & Africa: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
  • 9.6.4. Middle East & Africa: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • 9.6.5. Age-related Macular Degeneration (AMD) Market - Saudi Arabia
    • 9.6.5.1. Saudi Arabia: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
    • 9.6.5.2. Saudi Arabia: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 9.6.5.3. Saudi Arabia: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
    • 9.6.5.4. Saudi Arabia: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • 9.6.6. Age-related Macular Degeneration (AMD) Market - South Africa
    • 9.6.6.1. South Africa: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
    • 9.6.6.2. South Africa: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 9.6.6.3. South Africa: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
    • 9.6.6.4. South Africa: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • 9.6.7. Age-related Macular Degeneration (AMD) Market - Israel
    • 9.6.7.1. Israel: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
    • 9.6.7.2. Israel: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 9.6.7.3. Israel: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
    • 9.6.7.4. Israel: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • 9.6.8. Age-related Macular Degeneration (AMD) Market - UAE
    • 9.6.8.1. UAE: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
    • 9.6.8.2. UAE: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 9.6.8.3. UAE: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
    • 9.6.8.4. UAE: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
• 9.7. Age-related Macular Degeneration (AMD) Market - Latin America
  • 9.7.1. Latin America: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
  • 9.7.2. Latin America: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
  • 9.7.3. Latin America: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
  • 9.7.4. Latin America: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • 9.7.5. Age-related Macular Degeneration (AMD) Market - Mexico
    • 9.7.5.1. Mexico: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
    • 9.7.5.2. Mexico: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 9.7.5.3. Mexico: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
    • 9.7.5.4. Mexico: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • 9.7.6. Age-related Macular Degeneration (AMD) Market - Brazil
    • 9.7.6.1. Brazil: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
    • 9.7.6.2. Brazil: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 9.7.6.3. Brazil: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
    • 9.7.6.4. Brazil: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)
  • 9.7.7. Age-related Macular Degeneration (AMD) Market - Argentina
    • 9.7.7.1. Argentina: Age-related Macular Degeneration (AMD) Market, by Product, 2018 - 2030 (USD Billion)
    • 9.7.7.2. Argentina: Age-related Macular Degeneration (AMD) Market, by Distribution Channel, 2018 - 2030 (USD Billion)
    • 9.7.7.3. Argentina: Age-related Macular Degeneration (AMD) Market, by Drugs, 2018 - 2030 (USD Billion)
    • 9.7.7.4. Argentina: Age-related Macular Degeneration (AMD) Market, by Route of Administration, 2018 - 2030 (USD Billion)

10. Competitive Landscape

• 10.1. Expansion and Acquisition Analysis
  • 10.1.1. Expansion
  • 10.1.2. Acquisitions
• 10.2. Partnerships/Collaborations/Agreements/Exhibitions

11. Company Profiles

• 11.1. Acucela Inc.
  • 11.1.1. Company Overview
  • 11.1.2. Financial Performance
  • 11.1.3. Product Benchmarking
  • 11.1.4. Recent Development
• 11.2. Alimera Sciences Inc.
  • 11.2.1. Company Overview
  • 11.2.2. Financial Performance
  • 11.2.3. Product Benchmarking
  • 11.2.4. Recent Development
• 11.3. ALLERGAN
  • 11.3.1. Company Overview
  • 11.3.2. Financial Performance
  • 11.3.3. Product Benchmarking
  • 11.3.4. Recent Development
• 11.4. Bausch & Lomb Incorporated
  • 11.4.1. Company Overview
  • 11.4.2. Financial Performance
  • 11.4.3. Product Benchmarking
  • 11.4.4. Recent Development
• 11.5. Bayer AG
  • 11.5.1. Company Overview
  • 11.5.2. Financial Performance
  • 11.5.3. Product Benchmarking
  • 11.5.4. Recent Development
• 11.6. F. Hoffmann La Roche
  • 11.6.1. Company Overview
  • 11.6.2. Financial Performance
  • 11.6.3. Product Benchmarking
  • 11.6.4. Recent Development
• 11.7. GlaxoSmithKline PLC
  • 11.7.1. Company Overview
  • 11.7.2. Financial Performance
  • 11.7.3. Product Benchmarking
  • 11.7.4. Recent Development
• 11.8. Novartis AG
  • 11.8.1. Company Overview
  • 11.8.2. Financial Performance
  • 11.8.3. Product Benchmarking
  • 11.8.4. Recent Development
• 11.9. Ophthotech Corporation
  • 11.9.1. Company Overview
  • 11.9.2. Financial Performance
  • 11.9.3. Product Benchmarking
  • 11.9.4. Recent Development
• 11.10. Pfizer Inc
  • 11.10.1. Company Overview
  • 11.10.2. Financial Performance
  • 11.10.3. Product Benchmarking
  • 11.10.4. Recent Development
• 11.11. Regeneron Pharmaceuticals
  • 11.11.1. Company Overview
  • 11.11.2. Financial Performance
  • 11.11.3. Product Benchmarking
  • 11.11.4. Recent Development
• 11.12. Rxi Pharmaceuticals Inc.
  • 11.12.1. Company Overview
  • 11.12.2. Financial Performance
  • 11.12.3. Product Benchmarking
  • 11.12.4. Recent Development
• 11.13. Santen Pharmaceuticals Co.
  • 11.13.1. Company Overview
  • 11.13.2. Financial Performance
  • 11.13.3. Product Benchmarking
  • 11.13.4. Recent Development
• 11.14. Valeant Pharmaceuticals International, Inc.
  • 11.14.1. Company Overview
  • 11.14.2. Financial Performance
  • 11.14.3. Product Benchmarking
  • 11.14.4. Recent Development